Annual Report of Financial Year 2025-26

Sanjivani Paranteral Ltd FY26 financial highlights: - Revenue from operations at Rs 64.76 Cr, down 7.6% y-y - PAT at Rs 6.92 Cr, down 14.5% y-y - EBITDA margin at 16.4%, PAT margin at 10.7% - No dividend recommended for FY26 - Subsidiary SPL Infusion Pvt Ltd 60% owned; partnership with Alevia Healthcare S.R.O. - Board reconstituted with appointment of Mr. Basant Shrivastava as Independent Director - FY27 outlook: all three growth engines to contribute, scale and diversification expected - Export markets expanded in Latin America, Middle East, Africa - New manufacturing facility commissioned; focus on sterile injectables, IV infusions, nutraceuticals - Robust internal controls and compliance; no audit qualifications - AGM scheduled on 2026-09-16